SLS - SELLAS Life Sciences Group, Inc.

QQQ $ 479.35 $ 5.42 (1.14 %)

DIA $ 391.06 $ -2.96 (-0.75 %)

SPY $ 544.78 $ 2.09 (0.39 %)

TLT $ 94.49 $ 0.16 (0.17 %)

GLD $ 214.55 $ -1.07 (-0.5 %)

Previous Close

$ 1.17

Open

$ 1.24

Bid

$ 1.17 x 1,400

Ask

$ 1.18 x 100

Day's Range

$ 1.17 - $ 1.24

52 Week Range

$ 0.50 - $ 1.91

Volume

491,893

Average Volume

Market Cap

52.43M

Beta (5Y Monthly)

$ 1.28

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-14-2024	03-31-2024	10-Q
2	03-28-2024	12-31-2023	10-K
3	11-09-2023	09-30-2023	10-Q
4	08-10-2023	06-30-2023	10-Q
5	05-11-2023	03-31-2023	10-Q
6	03-16-2023	12-31-2022	10-K
7	11-14-2022	09-30-2022	10-Q
8	08-11-2022	06-30-2022	10-Q
9	05-12-2022	03-31-2022	10-Q
10	03-31-2022	12-31-2021	10-K
11	11-12-2021	09-30-2021	10-Q
12	08-12-2021	06-30-2021	10-Q
13	05-13-2021	03-31-2021	10-Q
14	03-23-2021	12-31-2020	10-K
15	11-13-2020	09-30-2020	10-Q
16	08-13-2020	06-30-2020	10-Q
17	05-14-2020	03-31-2020	10-Q
18	03-13-2020	12-31-2019	10-K
19	11-14-2019	09-30-2019	10-Q
20	08-14-2019	06-30-2019	10-Q
21	05-15-2019	03-31-2019	10-Q
22	03-22-2019	12-31-2018	10-K
23	11-14-2018	09-30-2018	10-Q
24	08-14-2018	06-30-2018	10-Q
25	05-15-2018	03-31-2018	10-Q
26	04-13-2018	12-31-2017	10-K
27	11-09-2017	09-30-2017	10-Q
28	08-14-2017	06-30-2017	10-Q
29	05-10-2017	03-31-2017	10-Q
30	03-15-2017	12-31-2016	10-K
31	11-09-2016	09-30-2016	10-Q
32	08-09-2016	06-30-2016	10-Q
33	05-10-2016	03-31-2016	10-Q
34	03-10-2016	12-31-2015	10-K
35	11-09-2015	09-30-2015	10-Q
36	08-06-2015	06-30-2015	10-Q
37	05-07-2015	03-31-2015	10-Q
38	03-05-2015	12-31-2014	10-K
39	11-05-2014	09-30-2014	10-Q
40	08-11-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

SELLAS Life Sciences Granted FDA Rare Pedi...
06/24/2024 13:05:45

why-ovid-therapeutics-shares-are-trading-lower-by-19-here-are-other-stocks-moving-in-mondays-mid-day-session

Why Ovid Therapeutics Shares Are Trading L...
06/17/2024 17:21:47

SELLAS Life Sciences Announced Review Of O...
06/17/2024 13:07:34

– The Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Trial Without Any Modifications ––...

$sellas-life-sciences-completes-enrollment-and-reports-positive-initial-data-from-phase-2a-trial-of-sls009-in-relapsedrefractory-acute-myeloid-leukemia$

SELLAS Life Sciences Completes Enrollment ...
06/10/2024 12:41:19

- 30 Patients Relapsed or Refractory to Venetoclax-Based Regimens Enrolled Ahead of Schedule - Overall Response Rate (ORR) of 3...

SELLAS Life Sciences Gr Q1 2024 Adj EPS $(...
05/14/2024 20:35:44

SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate...

SELLAS Announces Phase 2 Preliminary Data ...
05/01/2024 12:36:39

12-health-care-stocks-moving-in-mondays-intraday-session

12 Health Care Stocks Moving In Monday's I...
04/29/2024 16:31:20

SELLAS Life Sciences Announces Recommendat...
04/29/2024 12:55:53

– Based on the Efficacy and Safety Data Assessed, the Independent Data Monitoring Committee (IDMC) Recommends Continuation of P...

SELLAS Life Sciences Gr Q4 EPS $(0.25) Mis...
03/29/2024 03:35:30

SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate...

Sellas Life Sciences Group Files For Mixed...
03/28/2024 20:50:59

-S-3

$sellas-announces-topline-data-from-phase-2a-study-of-sls009-in-relapsedrefractory-acute-myeloid-leukemia-and-provides-steering-committee-update-on-phase-3-regal-study$

SELLAS Announces Topline Data From Phase 2...
03/26/2024 11:37:44

Phase 3 REGAL Study of GPS in AML: Enrollment Completed; Steering Committee Guided Interim Analysis Imminent; IDMC Now Schedu...